Business
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
LEXINGTON, Mass., April 23, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois. A poster presentation will highlight new translational data monitoring induced T-cell dynamics from the botensilimab and balstilimab (BOT/BAL) program in mismatch repair–proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal ca
About this update from Agenus Inc.
[{"type":"text","content":"LEXINGTON, Mass., April 23, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois. A poster presentation will highlight new translational data monitoring induced T-cell dynamics from the botensilimab and balstilimab (BOT/BAL) program in mismatch repair–proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC). In addition, two trials-in-progress presentations will showcase the design and scientific rationale of ongoing clinical studies evaluating botensilimab-based combinations in advanced pancreatic cancer.","length":731,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"text","content":"Presentation Title: Monitoring botensilimab and balstilimab induced T cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer.Presenting Author: Dr. Gertjan RasschaertPoster Session: Gastrointestinal Cancer—Colorectal and AnalSession Date and Time: May 31st, 2025; 9:00 AM-12:00 PM CDTAbstract Number: 3527Poster Number: 196","length":357,"tagName":"p"},{"type":"text","content":"Presentation Title: A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer. (NCT05632328)Presenting Author: Dr. Bruno BockornyPoster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliarySession Date and Time: May 31st, 2025; 9:00 AM-12:00 PM CDTAbstract Number: TPS423Poster Number: 506a","length":429,"tagName":"p"},{"type":"text","content":"Presentation Title: An open-label, phase 1 trial with expansion cohort of botensilimab (AGEN1181) + balstilimab (AGEN2034) + nab-paclitaxel + gemcitabine + cisplatin + chloroquine + celecoxib in adult patients with previously untreated metastatic pancreatic cancer. (NCT06076837)Presenting Author: Dr. Dan Van HoffPoster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliarySession Date and Time: May 31st, 2025; 9:00 AM-12:00 PM CDTAbstract Number: 507bPoster Number: TPS4234","length":508,"tagName":"p"},{"type":"text","content":"About Botensilimab (BOT)","length":24,"tagName":"p"},{"type"...